United Drug Supply Inc. | Pharmaceutical Distributor | Medical

Pharmacy Market

Medexus Pharmaceuticals | July 13, 2021

Medexus Pharmaceuticals Inc. announced today that it has entered into a licensing deal with medac GmbH to commercialize treosulfan, a bifunctional alkylating agent, in Canada. Treosulfan will be sold in Canada as Trecondyv and will be used in conjunction with fludarabine as part of a conditioning regime before allogeneic hematopoietic stem cell transplantation. Medexus will be in charge of selling and promoting the product, while Medac will manufacture and supply it. ...

CPD and Learning

Applied BioMath | December 09, 2020

Applied BioMath, the business chief in applying frameworks pharmacology and unthinking demonstrating, reproduction, and examination to de-hazard drug innovative work, today reported a joint effort with Antengene Corporation for the advancement of a frameworks pharmacology displaying in immuno-oncology. Applied BioMath will build up a frameworks pharmacology model for a PDL1/41BB bispecific immunizer, ATG-101, in immuno-oncology signs. The model will be utilized to anticipate clinical beginning a...

Pharma Tech

Globenewswire | May 12, 2023

SERB Pharmaceuticals, a global specialty pharmaceutical company, and SFJ Pharmaceuticals, a global drug development company, announce that SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ. Bentracimab is a novel, monoclonal antibody fragment designed to reverse the antiplatelet activity of ticagrelor. Ticagrelor, marketed by AstraZeneca as Brilinta®, is a reversible oral P2Y12 platelet inhibitor for patients who have suffered a hear...

Fiercepharma | June 10, 2020

As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to run phase 3 trials of vaccines from Moderna, AstraZeneca and Johnson & Johnson in the coming months, the Wall Street Journal reports. The NIH intends to start a phase 3 trial of Moderna’s vaccine in July, followed by an August trial of AstraZeneca’s vaccine and a September study of Johnson & Johnson&...